Head-to-head · WeighScore
DrBrainRx vs Hims & Hers
By GLP-1 ScorecardUpdated
Score comparison
Hims & Hers has the higher recorded score — 75.6/100 to 70.8/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | DrBrainRx | Hims & Hers |
|---|---|---|
| WeighScore | 70.8/100 | 75.6/100 |
| Grade | C | C |
| Site position | #110 | #56 |
| Semaglutide | $199/mo (all doses, compounded) | $199/mo |
| Tirzepatide | $299/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #110 · C
Strengths
- Founded and overseen by Dr. Sara Siavoshi — triple board-certified in Neurology, Headache Medicine, and Obesity Medicine
- LegitScript certified with compounded medications from USP-certified 503B pharmacies
- Flat-rate pricing — same monthly cost for all dose levels (dose escalation does not raise price)
- 100% online with rapid approvals (~24-48 hours) and discreet shipping in 3–5 business days
- Side-effect support, dose adjustments, and injection guides included with provider care
What to consider
- Separate $25/month provider care fee (compounded track) on top of medication cost
- Compounded medications are not FDA-approved individual drugs
- Labs not required or included — no baseline bloodwork protocol disclosed
- States served not published; no explicit list available
- No dedicated coaching program beyond clinical dose management
Site position #56 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
What to consider
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.